Evodiamine inhibits colorectal cancer cell stemness by disturbing ubiquitin specific protease 4 mediated SOX9 stabilization

被引:0
作者
Chen, Siqi [1 ,2 ,6 ]
Yang, Jinfeng [2 ,4 ]
Qi, Guangying [2 ,5 ]
Zhao, Jiawei [2 ,5 ]
Chen, Yujing [2 ,3 ]
Guo, Xiaotong [2 ,5 ]
Zhang, Juzheng [2 ,5 ]
Gan, Jinfeng [2 ,5 ]
Jian, Zhiyuan [1 ]
Jin, Jiamin [1 ,2 ,3 ,5 ]
机构
[1] Guilin Med Univ, Dept Gastrointestinal Surg, Affiliated Hosp, Guilin 541001, Peoples R China
[2] Guilin Med Univ, Key Lab Tumor Immunol & Microenvironm Regulat, Guilin 541199, Peoples R China
[3] Guilin Med Univ, Sch Pharm, Guilin 541199, Peoples R China
[4] Guilin Med Univ, Dept Immunol, Guilin 541199, Peoples R China
[5] Guilin Med Univ, Guangxi Hlth Commiss Key Lab Tumor Immunol & Recep, Guilin 541199, Peoples R China
[6] Tokushima Univ, Grad Sch Biomed Sci, Dept Oral Biosci, Tokushima, Japan
基金
中国国家自然科学基金;
关键词
Evodiamine; USP4; SOX9; Stemness; Colorectal cancer; CATENIN; INTERPLAY;
D O I
10.1007/s12672-025-02183-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Colorectal cancer (CRC) is the third most common cancer and the second most deadly cancer worldwide. It is of great importance to explore new mechanisms and therapeutic targets. Ubiquitin-specific protease 4 (USP4), as a key regulator of protein stability, has been proven to be closely associated with cancer progression. In addition, it has been found that evodiamine, a novel alkaloid, can effectively inhibit the stemness of colorectal cancer. Based on this, in this study, we explored in depth the interaction mechanism between USP4 and evodiamine in regulating cancer stemness. Our research data showed that the expression level of USP4 in CRC tissues and cells was significantly increased. Further experiments found that overexpression of USP4 could significantly enhance the migration and invasion of CRC and promote the expression of stemness-related genes such as SOX9, OCT4, and CD133. In contrast, knockdown of USP4 expression in CRC cells had the opposite effect. Moreover, USP4 promotes the progression of CRC by mediating the deubiquitination and stabilization of SOX9 protein. At the same time, evodiamine can significantly inhibit the expression of USP4, SOX9, OCT4, and CD133 in CRC cells. Its mechanism of action lies in the fact that evodiamine disrupts the deubiquitination process of USP4 on SOX9 protein, thereby effectively inhibiting the stemness of CRC. Developing an Evodiamine derivative will provide new approach for improving the outcome of CRC patients.
引用
收藏
页数:12
相关论文
共 25 条
  • [21] Targeting CRMP-4 by lentivirus-mediated RNA interference inhibits SW480 cell proliferation and colorectal cancer growth
    Chen, Si-Le
    Cai, Shi-Rong
    Zhang, Xin-Hua
    Li, Wen-Feng
    Zhai, Er-Tao
    Peng, Jian-Jun
    Wu, Hui
    Chen, Chuang-Qi
    Ma, Jin-Ping
    Wang, Zhao
    He, Yu-Long
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2016, 12 (04) : 2003 - 2008
  • [22] The synthetic flavonoid WYC02-9 inhibits colorectal cancer cell growth through ROS-mediated activation of MAPK14 pathway
    Chen, Yun-Ju
    Chen, Hsin-Pao
    Cheng, Yu-Jen
    Lin, Yu-Heng
    Liu, Kuang-Wen
    Chen, Yun-Ju
    Hou, Ming-Feng
    Wu, Yang-Chang
    Lee, Yi-Chen
    Yuan, Shyng-Shiou
    LIFE SCIENCES, 2013, 92 (22) : 1081 - 1092
  • [23] ZRANB1 enhances stem-cell-like features and accelerates tumor progression by regulating Sox9-mediated USP22/Wnt/β-catenin pathway in colorectal cancer
    Miao, Dazhuang
    Wang, Yan
    Jia, Yunhe
    Tong, Jinxue
    Jiang, Shixiong
    Liu, Lixiu
    CELLULAR SIGNALLING, 2022, 90
  • [24] miR-363-3p inhibits migration, invasion, and epithelial-mesenchymal transition by targeting NEDD9 and SOX4 in non-small-cell lung cancer
    Chang, Jingxia
    Gao, Feng
    Chu, Heying
    Lou, Lili
    Wang, Huaqi
    Chen, Yibing
    JOURNAL OF CELLULAR PHYSIOLOGY, 2020, 235 (02) : 1808 - 1820
  • [25] CBA (4-chloro-2-(2-chlorophenoxy)acetamido) benzoic acid) inhibits TMEM206 mediated currents and TMEM206 does not contribute to acid-induced cell death in colorectal cancer cells
    Kappel, Sven
    Melek, Korollus
    Ross-Kaschitza, Daniela
    Hauert, Barbara
    Gerber, Christian E.
    Lochner, Martin
    Peinelt, Christine
    FRONTIERS IN PHARMACOLOGY, 2024, 15